HOME - Luye Pharma Group

About Us

Luye Pharma Group (02186.HK), a member of Luye Life Sciences Group, is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications.

On The Road

Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech’s Dulaglutide Injection BA5101 in China

News

Yantai, May 15, 2023 – Boan Biotech, a subsidiary of Luye Pharma Group, today announced the completion of patient enrollment for the Phase III clinical trial (a comparative clinical study of efficacy and safety) of the company’s ...

May 15,2023

First Subject Enrolled in Boan Biotech’s International Multi-Center Phase 3 Clinical Study for Its Denosumab BA6101 & BA1102

Yantai, China, May 4, 2023 – Boan Biotech，a subsidiary of Luye Pharma Group, today announced that an international multi-center Phase 3 clinical study for its in-house developed Denosumab Injection (BA6101; BA1102) has been initiated in ...

May 04,2023

Luye Pharma and Duopharma Reach Strategic Partnership to Expand Accessibility of ...

Kuala Lumpur, Malaysia, April 5th, 2023 - Luye Pharma Group (Luye Pharma), an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications, today announced that it has entered an agreement with Duopharma Marketing Sdn Bhd, a wholly-owned subsidiary of Duopharma Biotech Berhad (Duopharma Biotech), which grants the latter exclusive marketing and distribution rights to a cholesterol management product in Malaysia.

April 05,2023

Luye Pharma Announces 2022 Financial Results

Yantai, China, March 29, 2023 - Luye Pharma Group (2186.HK) today announced its 2022 financial results and latest developments. During the reporting period, the group's revenue grew 15.0% year-on-year to RMB 5.982 billion approximately, its normalized EBITDA grew 44.8% year-on-year to RMB 1.963 billion approximately, and its normalized net profit attributable to shareholders grew 101.8% year-on-year to RMB 886 million approximately. Driven by the dual-strategy of "innovation + internationalization", the group’s fundamentals were significantly improving, with a clear path for growth. While several new drugs were approved for launch in China, Rykindo® (risperidone extended-release microspheres for injection) was also approved for launch in the U.S. That was exciting news, which marked a new chapter for the group in seeking global development. Driven by both new products and existing products, the group saw a growth of both revenue and profit. Besides, the group’s subsidiary Boan Biotech was successfully listed on the Hong Kong Stock Exchange (HKEX), representing a major step forward under the group’s global biopharmaceutical strategy.

March 29,2023

BLA Accepted in China for Boan Biotech’s Denosumab Injection (BA1102) for the ...

Yantai, China, March 21, 2023 — Luye Pharma Group today announced that the Biologics License Application (BLA) for BA1102 (Denosumab Injection), a biosimilar for the oncology indications developed by its ...

March 21,2023

Investors

July 19,2022

PHASE III CLINICAL TRIAL OF ROTIGOTINE EXTENDED-RELEASE MICROSPHERES FOR INJECTION (LY03003) IN PARKINSON’S DISEASE MET PRIMARY ...

Stock Code:02186.HK

Employee Stories

Upholding the philosophy of “Employee Development”,
Luye Pharma regards employees as the most valuable resources of the company

Historic Breakthrough, Brand New Journey The Story of Rykindo® (LY03004) Approval in the U.S.

To Learn and Grow through Problem Discovery and Resolution Yu Fei Director of Analytical Research and Development, R&D Center, Luye Pharma

Learn the Best of the People around You Yan Yameng HR BP, Luye Pharma

What I think When I Run Andy Siow APAC Commercial Director, Luye Pharma (International)

To Practice with Every Opportunity Wang Chao Director of Engineering Department II, Shandong Luye

My Three Years with Luye US Antonia Sacchetti Office Manager, Luye Pharma (US)